Using Whole-genome Bisulfite Sequencing to Understand Chromatin State Changes in Cancer

Clinical Trials, Life Sciences, Pharmaceutical, Pharmaceutical Regulation ,
  • February 26, 2014

Transcriptional regulation is accomplished by both focal cis-regulatory elements (promoters, enhancers, and insulators) and the higher order organization of chromosomes (topological domains). While these chromatin states are associated with a number of different epigenetic marks, DNA methylation (5-methylcytosine) is the most practical for studying primary tumors.

The presenters from University of Southern California and Epicentre (an Illumina company), will present on how whole-genome bisulfite sequencing (WGBS) is being used to profile dozens of primary tumors from The Cancer Genome Atlas (TCGA) project, how methylation can be accurately measured using next-generation sequencing, and a new method that yields comprehensive methylation coverage from small amounts of gDNA.

Speakers

Ben Berman, Ph.D., Assistant Professor, Division of Bioinformatics, Department of Preventive Medicine, University of Southern California Using Whole-genome Bisulfite Sequencing to Understand Chromatin State Changes in Cancer

Prof. Berman is an Assistant Professor in the Division of Bioinformatics of the Department of Preventive Medicine at the University of Southern California (USC). His current research focus is on whole-genome epigenomic analysis of cancer, control of gene regulation by non-coding regulatory elements and the role of nuclear organization alterations in cancer. He is also an active member of the USC Epigenome Center and the Norris Comprehensive Cancer Center, both of the University of Southern California.

Ramesh Vaidyanathan, Ph.D., Associate Director of Research and Development, Epicentre
Dr. Vaidyanathan is the Associate Director of Research and Development at Epicentre (an Illumina Company) located in Madison, WI. He received his Ph.D. from Indian Institute of Science, and was a Post Doctoral Associate at the Massachusetts Institute of Technology.

Ramesh Vaidyanathan, Ph.D., Associate Director of Research and Development, Epicentre Power of EpiGnome™: Comprehensive Methylation Coverage from Small Amounts of gDNA

Dr. Vaidyanathan is the Associate Director of Research and Development at Epicentre (an Illumina Company) located in Madison, WI. He received his Ph.D. from Indian Institute of Science, and was a Post Doctoral Associate at the Massachusetts Institute of Technology.

Who Should Attend?

  • Epigenetics or Epigenomics researchers
  • DNA Methylation researchers
  • Cancer and other disease biologists
  • Stem cell researchers
  • Sequencing core facilities
  • Next-generation sequencing facilities
  • R&D directors
  • Medical science liaisons

Xtalks Partners

Epicentre

Epicentre® (an Illumina Company) manufactures innovative products for life science research, contributing to breakthrough studies in genomics, transcriptomics, and epigenetics. Epicentre offers products for variety of applications, including ribosome profiling, RNA sequencing, gene expression analysis, DNA and RNA purification, PCR and RT-PCR, in vitro transcription, and microbial genomics.

Media Partners

Related Webinars

Sign Up or Login To Register for this Webinar

Interested in this webinar? Sign up to register for any upcoming or recorded webinar or if you’re already a member Login.

Sign Up